Viatris（VTRS）株式概要
ヴィアトリス・インクはその子会社とともに、北米、欧州、中国、台湾、香港、日本、オーストラリア、ニュージーランド、その他のアジア、アフリカ、中南米、中東でヘルスケア企業として事業を展開している。 詳細
VTRS Community Fair Values
Create NarrativeSee what 79 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$39.24
FV
57.6% 割安 内在価値ディスカウント113
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Viatris Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$16.65 |
| 52週高値 | US$17.53 |
| 52週安値 | US$8.32 |
| ベータ | 0.87 |
| 1ヶ月の変化 | 14.12% |
| 3ヶ月変化 | 3.64% |
| 1年変化 | 100.84% |
| 3年間の変化 | 82.77% |
| 5年間の変化 | 9.25% |
| IPOからの変化 | 2,615.41% |
最新ニュース
ナラティブの更新 • May 18
VTRS: FY26 Guidance And March Investor Event Will Shape Re Rating Potential
Analysts have raised their Viatris price target by $1.78 to $17.50, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research updates on Viatris point to a more constructive stance on the stock, with some firms lifting their valuation targets as they revisit earnings, cost savings and long term guidance assumptions.Seeking Alpha • May 11
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
Summary Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • May 18
VTRS: FY26 Guidance And March Investor Event Will Shape Re Rating Potential
Analysts have raised their Viatris price target by $1.78 to $17.50, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research updates on Viatris point to a more constructive stance on the stock, with some firms lifting their valuation targets as they revisit earnings, cost savings and long term guidance assumptions.Seeking Alpha • May 11
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
Summary Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now. Read the full article on Seeking Alpha
ナラティブの更新 • May 03
VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential
Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.ナラティブの更新 • Apr 19
VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential
Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.ナラティブの更新 • Apr 04
VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential
Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.ナラティブの更新 • Mar 21
VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential
Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.
ナラティブの更新 • Mar 07
VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations
Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.ナラティブの更新 • Feb 20
VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk
Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.ナラティブの更新 • Feb 06
VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential
Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.ナラティブの更新 • Jan 23
VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential
Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.ナラティブの更新 • Jan 09
VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns
Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.ナラティブの更新 • Dec 25
VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance
Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.ナラティブの更新 • Dec 11
VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance
Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.ナラティブの更新 • Nov 27
VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead
Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.ナラティブの更新 • Nov 13
VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead
The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.ナラティブの更新 • Oct 30
VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth
Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.ナラティブの更新 • Oct 15
Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.ナラティブの更新 • Aug 27
Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
新しいナラティブ • Apr 22
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Seeking Alpha • Feb 27
Viatris: One Swallow Doesn't Make A Summer
Summary Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 24
Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Summary Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition. In a sense, the "buy"/"sell" equation is simple: grow the business in 2025, and the stock price will rise. If the top-line shrinks, investors may lose faith. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
Summary We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this. Read the full article on Seeking AlphaSeeking Alpha • Nov 08
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Summary Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%. Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with greater than average product launches due to the Inflation Reduction Act. Recent earnings show revenue stabilization, driven by successful new product launches, with fewer divestitures moving forward. With a stronger balance sheet and increased capital for business development, Viatris is well-positioned for share-price appreciation and dividend growth. Viatris remains a strong buy due to new product launches, a bargain valuation at 5x forward earnings, and significant debt reduction to 3x EBITDA by year's end. Read the full article on Seeking Alpha株主還元
| VTRS | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 0.9% | 5.3% | 1.1% |
| 1Y | 100.8% | 44.3% | 28.7% |
業界別リターン: VTRS過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: VTRS過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。
価格変動
| VTRS volatility | |
|---|---|
| VTRS Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: VTRS 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: VTRSの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1961 | 30,000 | Scott Smith | www.viatris.com |
ヴィアトリス・インクは、その子会社とともに、北米、欧州、中国、台湾、香港、日本、オーストラリア、ニュージーランド、その他のアジア、アフリカ、中南米、中東でヘルスケア企業として事業を展開している。4つのセグメントで事業を展開している：先進国市場、グレーターチャイナ、JANZ、新興国市場の4つのセグメントで事業を展開している。医療用ブランド医薬品、ジェネリック医薬品、複合ジェネリック医薬品、バイオシミラー医薬品を提供している。また、循環器、中枢神経・麻酔、皮膚科、糖尿病・代謝、眼科、消化器、免疫、腫瘍、呼吸器・アレルギーなど、さまざまな非感染性疾患や感染症をカバーする治療領域の医薬品を提供するほか、診断クリニック、教育セミナー、患者の健康管理をサポートするデジタルツールなどのサポートサービスも提供している。さらに、経口固形剤、注射剤、複雑な剤形の医薬品を小売店や薬局、卸売業者や販売業者、支払者、保険会社や政府、機関などに提供している。リリカ、リピトール、セレブレックス、バイアグラ、クレオン、インフルバック、ウィクセラ・インハブ、エピペン自動注射器、フラクシパリン、ユペリ、ノルバスク、アミティーザ、エフェクサー、リパクレオン、ゾロフト、ザラブランズ、ダイミスタ、ザナックス、ブレイナのブランドで、医薬品卸・販売店、医薬品小売店、施設薬局、通信販売・Eコマース薬局、専門薬局を通じて製品を販売している。同社は、長時間作用型グラチラマー酢酸塩デポー製品および追加製品の開発・商業化に関するMapi Pharma Ltd.、ブランド生物学的製剤BOTOXのバイオシミラー製品の開発・製造・商業化に関するRevance Therapeutics, Inc.、レベフェナシンの開発・商業化に関するTheravance Biopharma, Inc.との提携契約を結んでいる。ヴィアトリス社は1961年に設立され、ペンシルベニア州キャノンズバーグに本社を置いている。
Viatris Inc. 基礎のまとめ
| VTRS 基礎統計学 | |
|---|---|
| 時価総額 | US$19.39b |
| 収益（TTM） | -US$296.50m |
| 売上高(TTM) | US$14.56b |
1.3x
P/Sレシオ-65.4x
PER（株価収益率VTRS は割高か？
公正価値と評価分析を参照収益と収入
| VTRS 損益計算書（TTM） | |
|---|---|
| 収益 | US$14.56b |
| 売上原価 | US$8.76b |
| 売上総利益 | US$5.80b |
| その他の費用 | US$6.09b |
| 収益 | -US$296.50m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.25 |
| グロス・マージン | 39.82% |
| 純利益率 | -2.04% |
| 有利子負債／自己資本比率 | 97.8% |
VTRS の長期的なパフォーマンスは？
過去の実績と比較を見る| Viatris 配当日 | |
|---|---|
| 配当落ち日 | May 22 2026 |
| 配当支払日 | Jun 17 2026 |
| 配当落ちまでの日数 | 4 days |
| 配当支払日までの日数 | 22 days |
VTRS 配当は確実ですか？
VTRS 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 21:33 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Viatris Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31
| アナリスト | 機関 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Aaron Gal | Bernstein |